AstraZeneca Inks $815M Deal To Develop Anemia Drug

Law360, New York (July 31, 2013, 2:19 PM EDT) -- British drug giant AstraZeneca LP has agreed to pay up to $815 million for the rights to an anemia treatment by San Francisco-based FibroGen Inc., which will be commercialized in markets including the U.S. and China, the firms said Wednesday. 

Under the terms of the deal, AstraZeneca will first pay FibroGen $350 million, and then follow up with milestone payments potentially up to $465 million, according to a joint statement by the firms. The deal also allows for additional payments tied to further sales-related milestones, the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.